ES2152255T3 - Precipitacion in situ de uno o mas compuestos activos. - Google Patents

Precipitacion in situ de uno o mas compuestos activos.

Info

Publication number
ES2152255T3
ES2152255T3 ES93915076T ES93915076T ES2152255T3 ES 2152255 T3 ES2152255 T3 ES 2152255T3 ES 93915076 T ES93915076 T ES 93915076T ES 93915076 T ES93915076 T ES 93915076T ES 2152255 T3 ES2152255 T3 ES 2152255T3
Authority
ES
Spain
Prior art keywords
active compounds
solution
situ precipitation
administration
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915076T
Other languages
English (en)
Inventor
Fredrik Broberg
Arne Brodin
Lisbet Rydhag
Sylvan G Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Ohio State University Research Foundation
Original Assignee
AstraZeneca AB
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, Ohio State University Research Foundation filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2152255T3 publication Critical patent/ES2152255T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA SOLUCION INYECTABLE PARA LA ADMINISTRACION DE UNO O MAS COMPUESTOS ACTIVOS. SEGUN LA INVENCION EL COMPUESTO ACTIVO, QUE SE PRESENTA EN SU FORMA NEUTRA, SE DISUELVE EN UN SOLVENTE BIOLOGICAMENTE ACEPTABLE CON EL QUE EL COMPUESTO ACTIVO SE PRECIPITA TRAS SU ADMINISTRACION FORMANDO UNA FASE SOLIDA DE LA SOLUCION IN SITU. DE ESTE MODO, DICHA SOLUCION, QUE ES FACIL DE ESTERILIZAR, ACTUA A MODO DE SUSPENSION CUANDO SE INYECTA.
ES93915076T 1992-07-09 1993-06-24 Precipitacion in situ de uno o mas compuestos activos. Expired - Lifetime ES2152255T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9202128A SE9202128D0 (sv) 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ

Publications (1)

Publication Number Publication Date
ES2152255T3 true ES2152255T3 (es) 2001-02-01

Family

ID=20386754

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915076T Expired - Lifetime ES2152255T3 (es) 1992-07-09 1993-06-24 Precipitacion in situ de uno o mas compuestos activos.

Country Status (16)

Country Link
US (1) US5916583A (es)
EP (1) EP0648112B1 (es)
JP (1) JP3809186B2 (es)
AT (1) ATE196990T1 (es)
AU (1) AU676177B2 (es)
CA (1) CA2139505C (es)
DE (1) DE69329576T2 (es)
DK (1) DK0648112T3 (es)
ES (1) ES2152255T3 (es)
FI (1) FI950074L (es)
GR (1) GR3035220T3 (es)
IS (1) IS4037A (es)
NO (1) NO950049L (es)
PT (1) PT648112E (es)
SE (1) SE9202128D0 (es)
WO (1) WO1994001087A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138130T3 (es) 1995-10-28 2000-01-01 Braun Melsungen Ag Composicion farmaceutica que contiene un anestesico local y/o un analgesico de accion central.
FR2748207B1 (fr) 1996-05-06 1998-06-12 Cird Galderma Composition a base d'un compose modulant la reactivite des fibres nerveuses
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
JP4865183B2 (ja) * 2000-06-06 2012-02-01 レキオファーマ株式会社 病変異常組織治療用医薬組成物キット
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
US7402320B2 (en) * 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
WO2006081238A2 (en) 2005-01-25 2006-08-03 Vnus Medical Technologies, Inc. Structures for permanent occlusion of a hollow anatomical structure
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US8465451B2 (en) 2005-06-22 2013-06-18 Covidien Lp Methods and apparatus for introducing tumescent fluid to body tissue
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
US9017361B2 (en) 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CA2914608A1 (en) * 2013-03-14 2014-09-25 Jsn I, Llc Taste masking of anesthetics and analgesics
LT3049055T (lt) * 2013-09-27 2018-07-25 Anteis S.A. Injekcinio hidrogelio, sterilizuoto karščiu, sudaryto iš hialurono rūgšties, turinčio miltelių pavidalo lidokaino ir šarminio agento, gamybos būdas
US20160367959A1 (en) * 2015-06-18 2016-12-22 Avon Products, Inc. Multiphase Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268495A (en) * 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4259331A (en) * 1979-04-16 1981-03-31 Pfizer Inc. Oxytetracycline compositions
US4599354A (en) * 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US5051257A (en) * 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.

Also Published As

Publication number Publication date
US5916583A (en) 1999-06-29
NO950049D0 (no) 1995-01-05
JP3809186B2 (ja) 2006-08-16
FI950074A0 (fi) 1995-01-05
NO950049L (no) 1995-01-05
PT648112E (pt) 2001-01-31
FI950074A7 (fi) 1995-01-05
AU676177B2 (en) 1997-03-06
DE69329576D1 (de) 2000-11-23
AU4519493A (en) 1994-01-31
CA2139505C (en) 2003-10-28
WO1994001087A1 (en) 1994-01-20
GR3035220T3 (en) 2001-04-30
SE9202128D0 (sv) 1992-07-09
ATE196990T1 (de) 2000-11-15
IS4037A (is) 1994-01-10
EP0648112A1 (en) 1995-04-19
DE69329576T2 (de) 2001-03-08
EP0648112B1 (en) 2000-10-18
FI950074L (fi) 1995-01-05
DK0648112T3 (da) 2000-11-27
CA2139505A1 (en) 1994-01-20
JPH07509450A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
ES2152255T3 (es) Precipitacion in situ de uno o mas compuestos activos.
PE52896A1 (es) Composicion farmaceutica
GT200000216A (es) Oxazolidinonas sustituidas y su uso.
AR019876A1 (es) Uso de una solucion liquida desinfectante que contiene un compuesto antimicrobiano para la desinfeccion composicion desinfectante que lo contiene
PE20000393A1 (es) Particulas de forma estable de compuestos organicos cristalinos
SV2002000969A (es) Composicion parenteral reconstituible
ES2083728T3 (es) Procedimiento para la preparacion de hidroximetil-5 furfural mediante catalisis heterogenea.
ES2113867T3 (es) Imino-derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2186197T3 (es) Procedimiento de solubilizacion de principios farmaceuticamente activos en agua y en vehiculos acuosos.
KR950007858A (ko) 정맥내 주사용 라파마이신 제형
ES2191678T3 (es) Administracion transdermica del eutomero de un farmaco quiral.
MX9302448A (es) Derivados iminicos ciclicos, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
AR026621A1 (es) Sistemas terapeuticos transdermales con estabilidad mejorada y un procedimiento para su preparacion
MA21864A1 (fr) Lauramides n-substitues, leur preparation et compositions les contenant
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
PE20040471A1 (es) Formulaciones de liberacion prolongada en forma de suspension
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
AR034854A1 (es) Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
AR004625A1 (es) Composicion de un oseo activo que comprende una sustancia de un oseo activo y un carrier bilogico de dicha sustancia,composicion farmaceutica que comprende dicha composicion de un oseo-activo,y uso de dicha composicion para la preparacion de un medicamento
AR038985A1 (es) Parecoxib sodico cristalino
AR034033A1 (es) Composicion farmaceutica a base de macrolidos para la aplicacion local en oftalmologia
ES2895772T1 (es) Solución de bortezomib lista para usar
ES2166098T3 (es) Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19951211

FG2A Definitive protection

Ref document number: 648112

Country of ref document: ES